Cannabis & Hemp-Derived Compounds: A Complete Guide to CBD, CBG, THC, and Hemp Nutrition

Few categories in natural health have generated more attention — or more confusion — than cannabis and hemp-derived compounds. The same plant family sits at the intersection of ancient herbal tradition, modern pharmaceutical research, a booming supplement market, and evolving legal frameworks. That combination makes it genuinely difficult for everyday readers to separate what the science actually shows from what's being marketed.

This page maps the full landscape: what these compounds are, how they work in the body, what the research does and doesn't support, and which individual factors shape how any given person might respond. The right place to start is with a clear distinction between the compounds themselves.

What "Cannabis & Hemp-Derived Compounds" Actually Covers

🌿 The term covers a broad family of biologically active substances derived from plants in the Cannabis sativa species — including both hemp and marijuana varieties. The key distinction between those two varieties, legally and practically, is tetrahydrocannabinol (THC) content. Hemp is generally defined (in U.S. federal law and many other jurisdictions) as cannabis containing less than 0.3% THC by dry weight. Marijuana varieties contain higher THC concentrations and remain federally controlled in the United States, though state laws vary significantly.

Within this category, the primary compounds that nutrition and wellness research has focused on include:

• Cannabidiol (CBD): A non-intoxicating cannabinoid found in both hemp and marijuana; the most widely studied for general wellness applications
• Tetrahydrocannabinol (THC): The primary psychoactive cannabinoid; the subject of clinical research for specific medical applications in jurisdictions where it is legal
• Cannabigerol (CBG): Sometimes called a "precursor" cannabinoid, present in smaller amounts; early research is exploring its properties
• Cannabinol (CBN): A mildly psychoactive compound that forms as THC degrades; early research is ongoing
• Hemp seed oil and hemp protein: Derived from the seeds rather than the flowers or leaves; nutritionally distinct from cannabinoid-rich extracts and not a significant source of CBD or THC
• Terpenes: Aromatic compounds found alongside cannabinoids that may interact with them in ways still being studied

Understanding which compound is actually in a product — and which part of the plant it came from — is one of the most important distinctions a reader can make before evaluating any health claim.

The Endocannabinoid System: Why These Compounds Affect the Body

The reason cannabis-derived compounds have biological effects at all comes down to a system most people have never heard of: the endocannabinoid system (ECS). This signaling network exists naturally in the human body and plays a role in regulating a range of physiological processes, including mood, sleep, appetite, pain signaling, and immune response.

The ECS operates through two primary receptor types — CB1 receptors, concentrated heavily in the brain and central nervous system, and CB2 receptors, found more broadly in immune tissues and peripheral organs. The body produces its own compounds (called endocannabinoids, such as anandamide) that bind to these receptors.

Plant-derived cannabinoids interact with this system — but not in identical ways. THC binds directly to CB1 receptors, which is what produces its psychoactive effects. CBD does not bind strongly to CB1 or CB2 receptors in the same way; instead, it appears to interact with the ECS more indirectly, potentially influencing how endocannabinoids are broken down and how other receptors respond. The mechanisms behind CBD's effects are still an active area of research, and much of the foundational work has been done in laboratory and animal studies — which don't always translate directly to human outcomes.

What the Research Actually Shows (and Where It's Uncertain)

The evidence base for cannabis and hemp-derived compounds is genuinely uneven, and that unevenness matters when evaluating any specific claim.

CBD is the compound with the most substantial clinical research behind it in a wellness context. The strongest human evidence involves a specific pharmaceutical-grade CBD formulation approved by the FDA for rare seizure disorders. Beyond that application, human clinical trial data remains limited or mixed for many of the uses most commonly discussed — including sleep, anxiety, and inflammation. Many studies have been small, short-term, or conducted without placebo controls. That doesn't mean the effects aren't real; it means the evidence base is still developing.

THC, in jurisdictions where it is legally available for medical use, has been more extensively studied for specific applications including chemotherapy-related nausea, appetite stimulation in wasting conditions, and certain pain types. These applications involve pharmaceutical-grade preparations at controlled doses — a very different context from general wellness supplementation.

Hemp seed nutrition is the most straightforward area. Hemp seeds are a well-established source of complete protein (containing all essential amino acids), along with a favorable ratio of omega-6 to omega-3 fatty acids. The nutritional profile of hemp seeds is relatively well-documented and doesn't depend on the same regulatory complexity as cannabinoid extracts.

The Variables That Shape Individual Response

🔬 Even setting aside questions about research quality, individual response to cannabinoids varies considerably — more so than with many conventional nutrients. Several factors influence how a person processes and responds to these compounds.

Metabolism and body composition play a role because cannabinoids are lipophilic — they dissolve in fat rather than water. This affects how they are absorbed, how they distribute through the body, and how long they remain in tissue. People with different body fat percentages may process cannabinoids differently.

Delivery method and formulation significantly affect bioavailability — the proportion of a compound that actually reaches systemic circulation in an active form. Inhaled forms reach the bloodstream quickly but carry separate respiratory considerations. Oral forms (oils, capsules, edibles) undergo first-pass metabolism in the liver, which reduces the amount reaching circulation and delays onset. Sublingual administration (held under the tongue) bypasses some first-pass metabolism. Water-soluble or nanoemulsified CBD formulations are designed to improve absorption, though the degree of improvement varies by product.

Existing medications are among the most clinically important considerations. CBD is metabolized by cytochrome P450 enzymes in the liver — the same enzyme family responsible for metabolizing a wide range of common medications. Research suggests CBD can inhibit these enzymes at sufficient doses, which could affect blood levels of other drugs. This is a general interaction pattern that healthcare providers and pharmacists are well-positioned to evaluate in specific contexts.

Age matters because the ECS changes across the lifespan, and older adults often have different baseline medication loads and metabolic rates. Pregnancy and breastfeeding represent contexts where research on cannabinoid safety is particularly limited, and guidance from health authorities reflects that uncertainty.

Dose is a complicating factor because responses to cannabinoids don't always scale linearly. Some research suggests CBD may follow a biphasic response curve — where effects at lower doses differ from effects at higher doses — though this hasn't been established clearly across all applications.

Key Questions This Sub-Category Addresses

Readers coming to cannabis and hemp topics are often asking very specific questions that deserve their own focused treatment.

The differences between CBD oil and hemp seed oil represent one of the most common points of confusion — two products frequently shelved together but derived from entirely different parts of the plant and with very different nutritional profiles and legal contexts. Understanding that distinction changes how a reader evaluates product labels.

Full-spectrum, broad-spectrum, and isolate CBD products represent another important distinction. Full-spectrum extracts retain THC (at trace levels in hemp-derived products), terpenes, and other cannabinoids alongside CBD. The "entourage effect" is the theory — still under investigation — that these compounds may work more effectively together than CBD in isolation. Broad-spectrum products aim to retain some of that complexity while removing THC. Isolate products are purified CBD alone. The research on whether these distinctions produce meaningfully different outcomes for users is still developing.

Drug testing is a practical concern many readers have, particularly with full-spectrum products. Even trace amounts of THC can accumulate with regular use and may appear on certain tests — a variable that depends on dose, frequency, individual metabolism, and the sensitivity of the test being used.

Hemp's nutritional role — separate from cannabinoids entirely — is a legitimate area of dietary interest. For readers exploring plant-based protein sources or omega fatty acid ratios, hemp seeds and hemp seed oil represent a well-established food option that doesn't carry the same regulatory complexity as cannabinoid extracts.

Topical versus systemic use represents a meaningful physiological distinction. Topically applied CBD products interact primarily with skin-level receptors; the degree to which they reach systemic circulation is generally considered limited, which has implications for both effects and safety — though research on topical bioavailability specifically is still limited.

Regulation, Quality, and the Label Problem

💡 One factor that shapes this entire sub-category more than almost any other is the regulatory environment. In the United States, CBD supplements are not approved by the FDA in the same way pharmaceuticals are. This means manufacturers are not required to demonstrate efficacy, and product quality is not uniformly verified before sale.

Independent testing has found that some CBD products contain significantly more or less CBD than their labels state, and some have contained unexpected THC levels. This makes third-party testing — certificates of analysis from independent labs — a meaningful factor when evaluating product reliability. It doesn't resolve questions about whether a compound works for a given purpose, but it does address the more basic question of whether the product contains what it claims.

Understanding this regulatory gap is part of understanding what it means to be an informed reader in this category. The research landscape, the legal landscape, and the product landscape are all moving at different speeds — and keeping those three separate is essential to drawing accurate conclusions about what is and isn't known.

What any given reader should make of all this depends on factors this page cannot assess: their current health status, medications, individual metabolism, the specific reason they're exploring these compounds, and the guidance of healthcare providers familiar with their complete picture.